Posted by Michael Wonder on 23 Dec 2018
Acorda Therapeutics announces FDA approval of Inbrija (levodopa inhalation powder)
21 December 2018 - Expected to be available by prescription in first quarter 2019.
Acorda Therapeutics today announced that the U.S. FDA approved Inbrija for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.
FDA approval of Inbrija was based on a clinical program that included approximately 900 people with Parkinson’s on a carbidopa/levodopa regimen experiencing OFF periods.
